Read More Pharma Industry News AstraZeneca’s Imfinzi demonstrates significant survival benefits in Phase 3 ADRIATIC trial In a significant advancement for cancer treatment, AstraZeneca’s Imfinzi (durvalumab) has emerged as the first and only immunotherapy… byPallavi MadhirajuApril 7, 2024